TABLE 2 An at-a-glance review of phosphate binders (16,17) Formulations Common adverse Medication available effects Notes Calcium Capsule, Hypercalcemia 25% elemental acetate tablet, oral calcium (PhosLo
, solution Eliphos, Phoslyra, Calphron) Calcium Chewable or Hypercalcemia 40% elemental carbonate non-chewable calcium (Turns, tablets others) Ferric Tablet Diarrhea, nausea, Increases serum citrate constipation, iron (Auryxia) dark-colored stool Lanthanum Chewable Nausea, vomiting, Less than .002% carbonate tablet, oral abdominal pain absorbed.
Ferric Citrate's pharmacodynamic properties resulted in increased ferritin and transferrin saturation (TSAT); whereas these parameters remained relatively constant in patients treated with active control (Renvela and/or Phoslo
According to one woman, "The generic version of PhosLo
made my feet swell.
received final approval from the Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for calcium acetate capsules, the generic equivalent of Phoslo
Gelcaps (calcium acetate) is an approved, effective, oral phosphate binder that is routinely used as a treatment option for hyperphosphatemia in patients with ESRD.
Fresenius executives attributed the growth to increased sales of products for peritoneal dialysis, as well as higher revenues from the phosphate binding drug PhosLo
and monies from intravenous iron products.
The program covers commonly prescribed bone disease medications, including Fosrenol, Hectorol, Phoslo
, Renagel, Sensipar, and Semplar.
The company has three products on the market today: PhosLo
(calcium acetate), Nabi-HB (Hepatitis B Immune Globulin (Human)), and Aloprim (allopurinol sodium) for Injection.
You probably will need to take a phosphate binder like PhosLo
, Tums, or calcium carbonate to control the phosphorus in your blood between dialysis sessions.
This milestone payment to Nabi Biopharmaceuticals was triggered by the first commercial sale of PhosLo
(calcium acetate) and related assets to Fresenius.
These assets included the rights to a new liquid formulation of PhosLo
that Fresenius has commercialised as Phoslyra.
The company attributes strong growth in North America to sales of its 2008K hemodialysis machines and the phosphate binding drug PhosLo
. The sale of dialyzers and peritoneal dialysis products contributed to international revenue growth, according to the company.